New drug trial targets aggressive breast cancer

NCT ID NCT06189209

Recruiting now Disease control Sponsor: Rhizen Pharmaceuticals SA Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called tenalisib in people with advanced triple-negative breast cancer that has spread to other parts of the body. The trial will enroll 40 patients who have already tried 1-3 chemotherapy treatments. Researchers want to see if the drug can shrink tumors, control cancer growth, and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

HCG City Cancer Center
RECRUITING

Vijayawada, Andhra Pradesh, 520002, India

Contact
Health Point Hospital
RECRUITING

Kolkata, West Bengal, 700025, India

Contact
Meenakshi Mission Hospital & Research Center
NOT_YET_RECRUITING

Madurai, Tamil Nadu, 625107, India

Contact
Mumbai Oncocare Centre
RECRUITING

Mumbai, Maharashtra, 400056, India

Contact
Narayana Hrudayala Majumdar Shaw Hospital
RECRUITING

Bangalore, Karnataka, 560099, India

Contact
Nizams Institute of Medical Science
NOT_YET_RECRUITING

Hyderabad, Telangana, 500082, India

Contact
Nobel Hospital
RECRUITING

Pune, Maharashtra, 411013, India

Contact
Sahyadri Super Speciality Hospital
RECRUITING

Pune, Maharashtra, 411004, India

Contact
Tata Memorial Centre
RECRUITING

Mumbai, Maharashtra, 400012, India

Contact

Conditions

Explore the condition pages connected to this study.

TRIPLE NEGATIVE BREAST CANCER (TNBC)